Summary Twenty-eight patients with progressive symptomatic bone metastases from breast cancer received (3-amino-l-hydroxypropylidene)-1,1-bisphosphonate (APD) 30mg in 500ml of 0.9% saline infused over 2h every 14 days. No other systemic therapy for breast cancer was prescribed. All patients had progressed on at least one previous systemic treatment. APD was continued until the disease progressed. Patients were assessed for objective response by the UICC criteria. In addition, subjective response was determined by a pain questionnaire.
Bone metastases are common in advanced breast cancer and a major cause of morbidity. Pain especially, but also pathological fracture, hypercalcaemia and bone marrow infiltration, cause disability. Palliation is possible with radiotherapy or systemic anticancer treatments and the clinical course is often long (Coleman & Rubens, 1987a) . However, progressive skeletal destruction leads to increasing immobility, a deterioration in quality of life and premature death.
Our understanding of the pathogenesis of skeletal metastases is incomplete but activation of osteoclasts is clearly relevant (Coleman & Rubens, 1985) . Tumour cells secrete a variety of paracrine factors which stimulate osteoclastic bone resorption. Normal coupling between osteoclast and osteoblast results in new bone formation although in metastatic bone disease this may be disturbed. Typically in advanced breast cancer resorption predominates and lytic bone metastases develop (Galasko, 1976) .
The diphosphonates (biphosphonates) are compounds containing a P-C-P structure by which they bind tightly to calcified bone matrix (Powell & Denmark, 1985) . Some, including (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD), are potent inhibitors of bone resorption. The mechanism of action is unclear but may involve direct biochemical effects on the osteoclast (Boonekamp et al., 1986) , prevention of osteoclast attachment to the bone matrix (Fleisch, 1982) or inhibition of osteoclast differentiation and recruitment (Boonekamp et al., 1987) . APD has been successfully used in the control of a variety of benign conditions characterised by increased bone resorption including Paget's disease (Harinck et al., 1987) , disuse and steroid-induced osteoporosis (Hoekman et al., 1985; Reid et al., 1988; Huaux et al., 1985) . APD is highly effective also for the control of hypercalcaemia of malignancy (Sleeboom et al., 1983; Ralston et al., 1985; Coleman & Rubens, 1987b ) and a recent study has shown that APD in combination with systemic anticancer treatment reduces the morbidity caused by tumour-induced osteolysis (van Holten-Verzanvoort et al., 1987 Objective, symptomatic and biochemical response to treatment were assessed. The UICC response criteria (Hayward et al., 1977) were used to assess objective response. A partial response was recorded when radiological evidence of sclerosis within previously lytic bone metastases was seen with no evidence of new lesions. The response category 'no change' indicated stabilisation of disease on plain radiographs for at least 3 months. An increase in the size of one or more baseline lesions or the appearance of new lesions was recorded as progressive disease. Purely sclerotic lesions were considered unassessable.
Two methods were used to assess symptomatic response: (1) a questionnaire recording pain intensity, analgesic consumption, mobility and performance status completed by the patient at each visit. A 'pain score' was derived from this information and expressed as a percentage of the maximum possible score (Table II) ; (2) a single question to the patient at 3 months (or sooner in the event of progressive disease) inquiring of the overall effect of treatment on quality of life.
Markers of bone metabolism used to follow the biochemical response to treatment were serum calcium, alkaline phosphatase and osteocalcin (BGP) and urinary calcium excretion. Monthly serum measurements of calcium, creatinine, alkaline phosphatase and phosphate were performed on a morning blood sample using a standard multi-channel autoanalyser. Serum for osteocalcin measurements was stored at -20°C and determined by radioimmunoassay using the Immuno Nuclear Osteocalcin RIA kit (Price et al., 1980) . A spot sample of urine was collected after an overnight fast and voiding of urine in the morning for measurement of urinary calcium excretion (Nordin, 1976) . All samples were collected on the morning before treatment with APD.
Results
Response of skeletal disease to treatment was assessable in 24 patients (Table III) . In 4 patients assessment was not possible because of either extra-skeletal progression (2 patients) or lack of follow-up data (2 patients). Radiographic evidence of bone healing (Figures 1 & 2) was seen in 4/24 this occasion the patient failed to respond. One patient remains on APD, in remission and off all analgesics, at 18 months. Two responding patients subsequently developed progressive disease outside the skeleton (liver 1 pt., skin lpt.) necessitating a change of treatment. Restaging at this time showed no evidence of progressive skeletal disease. Stabilisation of previously progressive bone disease for a minimum of 3 months (median 5 months, range 3-7 months) occurred in 11 patients (46%). Two had radiological evidence of sclerosis but radiographs of other sites showed new lytic areas. In 6, extraskeletal progression occurred, necessitating a change in treatment, before any evidence of deteriorating skeletal disease. The median time to progressive bone disease was 16 weeks (range 5-78 + weeks) and occurred within 3 months in 8 patients (33%). The median duration of survival has not been reached but is more than 38 weeks.
The mean pain score fell from 53% to 49% after 3 months' treatment. This change was not significant but 9 patients showed a > 10% improvement in symptom score. In 5 patients dramatic symptomatic improvement occurred allowing a major increase in mobility. All of these patients remain pain free more than a year later, 4 having discontinued opiate analgesia. All patients with symptomatic improvement had stabilisation of disease or bone healing on plain radiographs. Twelve patients reported global improvement in quality of life (Table III) patients (17%), in whom sclerosis of lytic lesions occurred with no evidence of new lesions. The sites undergoing sclerosis were outside the fields of previous radiotherapy.
The median duration of response was 10 months (range 9-18+). In one responding patient APD was stopped after 6 months' treatment and progression of disease was visible on plain radiographs 3 months later. APD was resumed but on hyperphosphataemia (serum phosphate > 1.5 mmol 1 -1). Two patients had grand mal convulsions; in one cerebral metastases were detected on CT brain scan but in the other no metabolic or structural cause could be found. No further fits since stopping APD have occurred and to date, metastatic disease has not developed in the central nervous system.
Discussion
In this study we have shown that APD, in the absence of any other systemic treatment for breast cancer, is able to halt the metastatic destruction of bone. Seventeen per cent showed evidence of bone healing on plain radiographs and 46% stabilisation of disease. Accompanying this was a reduction in pain score and increased mobility. Symptomatic response was occasionally dramatic and osteolytic destruction inhibited for many months. Although not formally tested there was an indication that APD improved quality of life. Treatment was well tolerated. Biochemical improvement has been noted in previous studies of diphosphonates in metastatic bone disease (van Holten-Verzantvoort et al., 1987; Elomaa et al., 1983; van Breukelen et al., 1974; Siris et al., 1980) , and a reduction in morbidity reported in placebo-controlled studies (van Holten-Verzantvoort et al., 1987; Elomaa et al., 1983) . Inhibition of new lesion formation has been noted in animal (Jung et al., 1984) and human studies (Elomaa et al., 1985) but none have reported radiological improvement in metastatic bone disease.
The diphosphonates possess no cytotoxic or immunosuppressive activity (Garattini et al., 1987) and so the structural improvement in bone lesions in some patients needs alternative explanation. In metastatic bone disease bone formation and resorption rates are typically increased (Delmas et al., 1987; Coleman et al., 1988) . Specific inhibition of bone resorption stops the efflux of calcium from the skeleton while continuing osteoblast activity permits new bone formation to occur (Parfitt, 1980 ). An acute increase in the bone mass following treatment with APD has been seen in normal rat bone (Reitsma et al., 1980) , bone affected by the mouse 5T2 multiple myeloma (Radl et al., 1985) and patients with steroid-induced osteoporosis (Reid et al., 1988) .
The optimum schedule and route of administration of APD has not been defined. We have shown previously that a single intravenous dose of 15-30mg of APD will control hypercalcaemia secondary to advanced breast cancer for a median of 11 days (Coleman & Rubens, 1987b) . Multi-dose and single dose intravenous infusions of APD appear to be equally effective in the treatment of hypercalcaemia of malignancy (Yates et al., 1987) and above a dose of 0.25mgkg-1 there does not appear to be a dose-response relationship (Body et al., 1987) . On the basis of these data we selected the two-weekly schedule and dose of intravenous APD used in this study.
Extra-skeletal progression was common and the reason for changing treatment in 12 patients. This presumably reflects the lack of specific anticancer treatment. Whether this had any influence on the development of bone marrow infiltration and spinal cord compression through intra-medullary and epidural extension is speculative, but the incidence of these complications was higher than we would have expected (Coleman & Rubens, 1987a) .
In conclusion, we have shown that APD is an effective drug for inhibiting bone resorption secondary to advanced breast cancer. The role of APD in conjunction with systemic antitumour therapy for the treatment and prevention of bone metastases is now being studied in a controlled randomised trial.
